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Purpose: Definitive radiation therapy (RT), with or without concurrent chemotherapy, is an alternative to radical cystectomy for patients with localized, muscle-invasive bladder cancer (MIBC) who are either not surgical candidates or prefer
organ preservation. We aim to synthesize an evidence-based guideline regarding the appropriate use of RT.
Methods and Materials: We performed a Preferred Reporting Items for Systematic Reviews and Meta-analyses literature review using the PubMed and Embase databases. Based on the literature review, critical management topics were
identified and reformulated into consensus questions. An expert panel was assembled to address key areas of both
consensus and controversy using the modified Delphi framework.
Results: A total of 761 articles were screened, of which 61 were published between 1975 and 2019 and included for full
review. There were 7 well-designed studies, 20 good quality studies, 28 quality studies with design limitations, and 6
references not suited as primary evidence. Adjuvant radiation therapy after cystectomy was not included owing to lack
of high-quality data or clinical use. An expert panel consisting of 14 radiation oncologists, 1 medical oncologist, and 1
urologist was assembled. We identified 4 clinical variants of MIBC: surgically fit patients who wish to pursue organ
preservation, patients surgically unfit for cystectomy, patients medically unfit for cisplatin-based chemotherapy, and
borderline cystectomy candidates based on age with unilateral hydronephrosis and normal renal function. We identified
key areas of controversy, including use of definitive radiation therapy for patients with negative prognostic factors,
appropriate radiation therapy dose, fractionation, fields and technique when used, and chemotherapy sequencing and
choice of agent.
Conclusions: There is limited level-one evidence to guide appropriate treatment of MIBC. Studies vary significantly
with regards to patient selection, chemotherapy use, and radiation therapy technique. A consensus guideline on the
appropriateness of RT for MIBC may aid practicing oncologists in bridging the gap between data and clinical practice.
Ó 2020 Elsevier Inc. All rights reserved.

Introduction
An estimated 80,470 Americans received a diagnosis with
bladder cancer in 2019, and there were 17,670 deaths
related to this disease.1 Approximately 25% of bladder
cancers are muscle-invasive (MIBC) at diagnosis, for which
radical cystectomy (RC) is the most common treatment in
the United States.2-4 RC results in 5-year recurrence-free
and overall survival of 53% to 89% and 44% to 77%,
respectively. However, surgery can be associated with significant perioperative risk as well as diminished quality of
life due to urinary, gastrointestinal, and sexual dysfunction.5,6 Radiation-based therapy (RT), with concurrent
chemotherapy when possible, commonly referred to as
bladder preservation (BP), is an established treatment option for patients who are medically unfit for RC or who
seek a nonsurgical alternative.7,8 Indeed, the National
Comprehensive Cancer Network guidelines has evolved to
incorporate chemoradiation-based BP as a category 1
recommendation for primary treatment in 2020.9 For wellselected patients who are otherwise surgical candidates,
bladder conservation preserves function and may result in
similar oncologic outcomes compared with RC. However,
the only contemporary randomized trial attempting to
compare outcomes between RC and RT failed to accrue.10
Despite the lack of randomized data demonstrating the
superiority of surgery versus RT, bladder preservation

accounts for only 7% to 9% of treatments for MIBC in the
United States.11 The complexity and multidisciplinary nature of MIBC treatment can result in widely disparate
management decisions,12 and there exists a pressing need
for evidence-based treatment criteria. Here, we present an
executive summary of the American Radium Society
(ARS) appropriate use guideline for RT for MIBC based
upon a systematic review of the evidence. This guideline
will focus on lymph node-negative MIBC, as there is a
paucity of clinical data on the use of definitive-intent radiation therapy in patients with node-positive MIBC.
Similarly, management in the palliative setting, including
many well-described hypofractionated RT regimens,13,14
were beyond the scope of this panel. Little data exist for
postoperative treatment of MIBC, which is not widely
adopted nationally. For patients with node-positive MIBC,
we strongly encourage clinical trial participation as available (eg, NRG 8185). Consistent with previous guidelines,
this ARS panel recommends that patients be evaluated and
advised of their treatment options in a multidisciplinary
manner.8

Methods and Materials
A systematic literature review using the PubMed (Medline)
and Embase (Elsevier) databases was completed between
January 18, 2019 to March 18, 2019 per the Preferred
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Table 1

Literature search strategy

Search index
1
2

3
4

5
6

ARS appropriateness guideline for RT for muscle invasive bladder cancer

Search terms

No. of references

Bladder cancer[title] OR
bladder carcinoma[title]
1 OR transitional cell
carcinoma[title] OR
urothelial carcinoma[title]
2 AND “invasive” [title/
abstract])
3 AND “radiation[title/
abstract] OR radiation
therapy[title/abstract] OR
radiation therapy[title/
abstract] OR
chemorad*[title/abstract]
Limit 4 to English language
Limit 5 to human subjects

21,282
28,636

7740
997

901
761

Reporting Items for Systematic Reviews and MetaAnalyses declaration.15 The search strategy is presented
in Table 1 and the literature review flowchart is presented in
Fig. 1. References were sequentially screened by title, abstract, and full text for relevance. Articles included for full
review were assessed for quality according to relevance,
study design, sample size, generalizability of endpoints,
follow-up time, and assessment protocols. Three additional
references were included for review at the discretion of the
senior authors.
An expert panel consisting of 14 radiation oncologists, 1
medical oncologist, and 1 urologist from 14 US institutions
was assembled. After reviewing available evidence, key
clinical questions were addressed using a modified Delphi
consensus framework.16

Results
Fifty-eight studies were included, with an addition of 3
reference sources, to create an evidence table (Table E1).
Of these, there are 7 well-designed randomized trials, 20
good quality trials, 28 quality studies with design limitations, and 6 references that may not be useful as primary
evidence. Each study is summarized in the evidence table,
which can be found in the Supplementary Materials. Two
rounds of voting were completed pertaining to the appropriateness of key management decisions for 4 clinical
variants of MIBC that encompass an inclusive range of
scenarios.

Who can be offered bladder preservation therapy?
Patient selection is paramount for bladder preservation.
Nearly all studies reviewed included patients with cT2-T4
cN0 cM0 disease (Table E1). Some series included nodepositive patients,17-23 but most contemporary trials have
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excluded clinically or pathologically confirmed lymph node
metastases.24-27
Patients who are otherwise fit for RC should typically
also be candidates for chemotherapy as a part of BP.
Although radical RT alone demonstrated 5-year overall
survival (OS-5y) ranging from 16% to 28%,17,28-32 combined chemoradiotherapy regimens resulted in OS-5y
ranging from 52% to 74%.18,27,33-36 Patients should undergo an attempted maximally complete trans-urethral
resection of bladder tumor (TURBT), defined as no visible
tumor on cystoscopy and negative urine cytology. A number of analyses of large prospective studies from Germany,
the United States, and Australia have demonstrated that the
extent of TURBT is a strong prognostic factor for survival.30,34,37,38 Ureteral obstruction leading to hydronephrosis may be a negative prognostic factor for outcomes
after BP. In the Massachusetts General Hospital (MGH)
experience, the presence of hydronephrosis was associated
on univariable analysis with decreased CR rate (68% vs
37%, P Z .002), a 79% increased risk of death (P < .001),
and 2-fold increased risk of disease specific mortality (P Z
.001).38,39 Hydronephrosis became an exclusion criteria in
the RTOG studies after 1993, although patients with
hydronephrosis were included in most subsequent European and Australasian studies.19,34

Discussion
There is weak evidence to suggest that multifocal disease
portends poor outcomes after BP. Rodel et al reported that
multifocal disease was prognostic of lower rates of local
control (LC, 52% vs 39%, P Z .08).37 However, multifocality was not associated with CR, distant metastasis
(DM), or OS. Although carcinoma-in situ (CIS) is an
exclusion criterion in many trials, the prognostic significance of CIS is also uncertain. In the MD Anderson Cancer
Center radical RT series, the presence of CIS was associated with a 52% and 57% hazard of poorer OS and LC,
respectively.17 However, CIS was not shown to effect outcomes in the MGH or German experiences, in which patients received chemotherapy.37,38
Patient-specific factors are important in the selection
process for BP in operable candidates. Some patients with
MIBC previously have undergone many sequential TURBTs
and intravesical instillation therapies, which can negatively
affect baseline bladder function. Because RT to the whole
bladder is known to further diminish function, baseline
bladder performance should be adequate enough to attempt
BP.40 In the case of in-bladder recurrence, salvage cystectomy often is effective and should be promptly considered.24,35,41-43 Patients must be motivated to participate in
routine surveillance to detect in-bladder recurrences early.
In cases where patients who are not surgical candidates
or decline RC, there was consensus to strongly recommend
RT-based treatment (Tables 2-4). Hydronephrosis, multifocal disease, CIS, tumor size, as well as T-stage are
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Identification
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Records identified through
datadase searching
(n = 761)

Additional records identified
through other sources
(n = 3)

Eligibility

Records screened
(n = 698)

Full-text articles assessed
for eligibility
(n = 125)

Included

Screening

Records after duplicates removed
(n = 698)

Studies included in
qualitative synthesis
(n = 61)

Fig. 1.

Records excluded by
abstract relevance
(n = 576)

Full-text articles excluded
Low relevance: n = 42
Non-muscle invasive: n = 19
English abstract only: n = 3

Preferred Reporting Items for Systematic Reviews and Meta-analyses flowchart.

interrelated and are likely proxies for the underlying cancer
biology. As such, these covariates also negatively affect
outcomes after radical cystectomy.2-4 When multiple risk
factors suggest a high likelihood of local failure after MMT,
neoadjuvant chemotherapy with immediate radical cystectomy may be more appropriate for surgical candidates
(Table 5).

What are the optimal neoadjuvant, concurrent, or
adjuvant chemotherapy options?
Concurrent chemotherapy with RT (CCRT) is the most
widely adopted regimen for BP.7,8 Cisplatin has been the
most commonly used agent in North America, Australia,
and Germany.21,34,43 Cisplatin can often be combined with
either paclitaxel or 5-FU as part of CCRT.25,44,45 For patients ineligible for cisplatin due to poor renal function or
hearing impairment, alternate CCRT regimens include
5-FU plus mitomycin-C,24 paclitaxel,46,47 or carboplatin.37
Outcomes for these regimens are comparable, with CR
rates of approximately 70%. More recently, gemcitabinebased CCRT have resulted in even higher CR rates reaching up to 93%.19,27,36,48-53 RTOG 0712 is a randomized
phase 2, multicenter study that evaluated concurrent CCRT

with either 5-FU/cisplatin or low-dose gemcitabine.26 The
rates of CR were 88% and 78%, respectively. Distantmetastasis free survival at 3 years was 78% and 84%,
respectively. The ongoing phase 2 trial GETUG V04
compares cisplatin and gemcitabine-based CCRT.52
Cisplatin-based CCRT was preferred by the panel for patients undergoing BP with adequate renal function,
however, nonplatinum CCRT also was deemed appropriate
(Tables 2-4).
Neoadjuvant chemotherapy before RT for BP has been
explored in 2 randomized trials. BA-06 randomized patients to neoadjuvant methotrexate, cisplatin, and vinblastine (MCV) followed by radical local therapy (RT or
cystectomy) versus radical local therapy alone.42 CCRT
was not used. Neoadjuvant MCV was shown to improve OS
at 5 years by 6% (39% vs 43%, P Z .037). RTOG 8903
compared neoadjuvant MCV followed by cisplatin-based
CCRT versus CCRT alone.54 There were no significant
differences in CR, OS, DM, or bladder conservation rates.
This trial closed early owing to high rates of neutropenia
and sepsis leading to 3 treatment-related deaths. The high
rates of MCV-related toxicity recapitulated results of an
earlier phase 2 study, in which there were 4 sepsis-related
deaths during neoadjuvant treatment.55 As a caveat, the
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Table 2 Clinical variant 1, a 67-year-old, current smoker, sexually active man with a recent diagnosis of a 3 cm cT2 cN0 M0
transitional cell carcinoma of the posterior wall of bladder who is fit for radical cystectomy, but would like to avoid RC due to concerns
regarding erectile dysfunction after surgery
Procedure
External beam RT
Split course XRT
Continuous course XRT
Neoadjuvant chemotherapy
Concurrent cisplatin-based
chemotherapy
Concurrent noncisplatin-based
chemotherapy
Adjuvant chemotherapy, in
absence of neoadjuvant
chemotherapy
Maximal TURBT
IMRT
3D conformal RT
Elective pelvic nodal XRT

Rating
category

Group median
rating

Disagree

References

SQ

SOE

SOR

16-19,21-29,31,34-55,57-61

1
1
1
1
1

S
S
S
M
S

[
Y
[
Y
[

A
A*
A
M
A

8
5
8.5
5
9

A

7

25-30,32-34,44,46,50

1

S

[

M

4.5

37,38,47,49

2

L

Y

A
A
A
M*

9
7
8
5

22-61

1
3
1
2

S
M
S
M

[
[
[
Y

X

35,36,39,42,45-49,51,53
23-34,37,40,41,43,44,50-52,54-56,58,59,61
39,41-46,48,61
20,22-24,31,35-40,42-49,53-56,61

56
16-19,21-29,31,34-55,57-61

X

21,22,30,35,36,38-40,42,44,45,47-49,54,56,57,61

Abbreviations: 3D Z 3-dimensional; IMRT Z intensity-modulated radiation therapy; RC Z radical cystectomy; RT Z radiation therapy.
Rating: A Z usually appropriate; M Z may be appropriate; U Z usually not appropriate.
Strength of evidence: S Z strong; M Z moderate; L Z limited; EC Z expert consensus; EO Z expert opinion.
Study quality: 1 Z well designed; 2 Z good quality; 3 Z good quality with limitations; 4 Z may not be useful as primary reference.
Strength of recommendation: [ Z strong recommendation; Y Z weak recommendation; - Z additional considerations do not strengthen or weaken the
panel’s recommendation.
* Disagreement (ie, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation; see
narrative text). Group median rating is set automatically to 5.

Table 3 Clinical variant 2, an 80-year-old, female patient with COPD and CAD with a 4 cm cT3 cN0 M0 TCC of the bladder dome,
who is determined by urology team to be medically unfit for radical cystectomy
Procedure
External beam RT
Split course XRT
Continuous course XRT
Neoadjuvant chemotherapy
Concurrent cisplatin-based
chemotherapy
Concurrent noncisplatin-based
chemotherapy
Adjuvant chemotherapy, in
absence of neoadjuvant
chemotherapy
Maximal TURBT
IMRT
3D conformal RT
Elective pelvic nodal XRT

Rating
category

Group median
rating

Disagree

References

SQ

SOE

SOR

13-61

1
1
1
1
1

S
S
S
M
S

[
Y
[
Y
[

25-30,32-34,44,46,50

1

S

[

A
M*
A
M
A

8.5
5
9
5
8

A*

5

M

4

37,38,47,49

2

L

Y

A
A
A
M*

9
7
8
5

22-61

1
3
1
2

S
M
S
M

[
[
[
Y

X

35,36,39,42,45-49,51,53
23-34,37,40,41,43,44,50-52,54-56,58,59,61
39,41-46,48,61
20,22-24,31,35-40,42-49,53-56,61

X

56
13-61

X

21,22,30,35,36,38-40,42,44,45,47-49,54,56,57,61

Abbreviations: 3D Z 3-dimensional; CAD Z coronary artery disease; COPD Z chronic obstructive pulmonary disease; IMRT Z intensity-modulated
radiation therapy; RC Z radical cystectomy; RT Z radiation therapy.
Rating: A Z usually appropriate; M Z may be appropriate; U Z usually not appropriate.
Strength of evidence: S Z strong; M Z moderate; L Z limited; EC Z expert consensus; EO Z expert opinion.
Study quality: 1 Z well designed; 2 Z good quality; 3 Z good quality with limitations; 4 Z may not be useful as primary reference.
Strength of recommendation: [ Z strong recommendation; Y Z weak recommendation; - Z additional considerations do not strengthen or weaken the
panel’s recommendation.
* Disagreement (ie, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation; see
narrative text). Group median rating is set automatically to 5.
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Table 4 Clinical variant 3, a 67-year-old male previous smoker with stage 3 chronic kidney disease and a new diagnosis of a 3 cm cT2
cN0 M0 TCC of the right wall of bladder
Procedure
External beam RT
Split course XRT
Continuous course XRT
Concurrent carbogen and
nicotinamide
Concurrent 5-FU/MMC
chemotherapy
Concurrent gemcitabine-based
chemotherapy
Maximal TURBT
IMRT
3D conformal RT
Elective pelvic nodal XRT

Rating
category

Group median
rating

A
M*
A
M*

8
5
8.5
5

A

7.5

A
A
A
A
M

Disagree

References

SQ

SOE

SOR

14-19,21,25-30,32-34,44,50

1
3
1
1

S
S
S
M

[
Y
[
Y

21,24,50,55

1

S

[

8

25-30,32-34,49

2

S

[

7.5
8
7.5
6

22-30,32-34,44,50

1
3
1
2

S
M
S
M

[
[
[
Y

X

46
25-30,32-34,44,50

X

59,60

56
14-19,21,25-30,32-34,44,50
21,30,44

Abbreviations: 3D Z 3-dimensional; IMRT Z intensity-modulated radiation therapy; RC Z radical cystectomy; RT Z radiation therapy.
Patient was deemed unable to receive cisplatin by medical oncology team due to his poor renal function.
Rating: A Z usually appropriate; M Z may be appropriate; U Z usually not appropriate.
Strength of evidence: S Z strong; M Z moderate; L Z limited; EC Z expert consensus; EO Z expert opinion.
Study quality: 1 Z well designed; 2 Z good quality; 3 Z good quality with limitations; 4 Z may not be useful as primary reference.
Strength of recommendation: [ Z strong recommendation; Y Z weak recommendation; - Z additional considerations do not strengthen or weaken the
panel’s recommendation.
* Disagreement (ie, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation; see
narrative text). Group median rating is set automatically to 5.

initial eligibility criteria for RTOG 8903 included patients
with 24-hour creatinine clearance as low as 50 mL/min and
serum creatinine up to 2.0 mg/dL. After the protocol was
modified to require better baseline renal function, no
additional grade 4 or 5 toxicity was seen in subsequent
patients. Several retrospective reports have indicated the
safety of neoadjuvant chemotherapy regimens, followed by
CCRT, with excellent outcomes: CR, OS, and cancerspecific survival (CSS) rates range from 73% to 86%,
68% to 72%, and 76% to 79%, respectively.56-59 Neoadjuvant chemotherapy was rated as potentially appropriate, with a weak recommendation (Tables 2, 3, and 5).
The benefit of adjuvant chemotherapy therapy after CCRT
is unclear and to date, there are no published randomized
trials comparing CCRT with and without adjuvant chemotherapy. RTOG 9706, 9906, and 0233 were nonrandomized
phase 1 or 2 trials adding MCV or cisplatin/gemcitabine as
adjuvant therapy, resulting in 5-year OS ranging from 56% to
more than 70%.25,44,45 As expected, adjuvant treatments
came at the expense of more than 50% to 70% of patients in
these trials experiencing acute grade 3 to 4 toxicities. Adjuvant chemotherapy was rated as potentially appropriate, with
a weak recommendation (Tables 2, 3, and 5).

What radiation dose and fractionation are most
appropriate?
Radiation therapy can be delivered as a continuous or a
split coursedthe latter to allow for response assessment for

potential immediate salvage cystectomy. For operable patients who refuse surgery, continuous course RT is
acceptable and recommended. In the largest series using
continuous course, RT was delivered to a maximum dose of
55.8 to 65 Gy in standard fractions to the tumor or whole
bladder.24,34,35,60 Outcomes were not clearly better with
higher dose: in one series where patients received less than
60 Gy, the CR rate was 88.4%, whereas CR was 70% in a
separate series in which patients received 63 to 64 Gy.
However, these comparable results are confounded by differences including patient selection, chemotherapy regimens, and radiation therapy techniques.
Split-course treatment has the advantage of responseadapted, immediate salvage cystectomy before completion
of a definitive course of radiation therapy. This can be
advantageous given the potentially increased morbidity of
cystectomy after high dose pelvic RT.41,61 Additionally, CR
after RT is a strong predictor of overall survival, and early
salvage for patients without CR after induction RT may be
beneficial.17,37 In the MGH selective bladder sparing protocol, 39.6 Gy was delivered in 1.8 Gy fractions to the
entire pelvis, followed by a break to evaluate for response,
followed by an additional 25.2 Gy to the tumor plus margin
for complete responders.54
A potential disadvantage to split-course RT is that the
prolonged total treatment time can result in decreased
biological effectiveness.62 In a large retrospective Dutch
study, there was a trend toward inferior locoregional control
with longer total treatment times (47% for greater than 75
days vs 63% for less than 75 days, P Z .08).22 There was
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Table 5 Clinical variant 4, an 80-year-old woman with diabetes and hypertension with a 6 cm cT3 cN0 M0 TCC of the left and
posterior walls of the bladder with obstruction of the left ureteral orifice, resulting in left-sided hydronephrosis, with normal renal
function
Procedure
Bladder preservation if patient is
a good candidate for RC, but
desires bladder preservation
Bladder preservation if patient is
a good candidate for RC, but
refuses surgery
Bladder preservation if patient is
not a RC candidate
Neoadjuvant chemotherapy
Concurrent cisplatin-based
chemotherapy
Concurrent noncisplatin-based
chemotherapy
Adjuvant chemotherapy, in
absence of neoadjuvant
chemotherapy
Maximal TURBT
IMRT
3D conformal RT
Elective pelvic nodal XRT

Rating
category

Group median
rating

Disagree

References

SQ

SOE

SOR

X

16-19,21-29,31,34-55,57-61

1

S

Y

M*

5

A

7

16-19,21-29,31,34-55,57-61

1

S

[

A

9

13-61

1

S

[

M
A

5.5
7.5

39,41-46,48,61

1
1

M
S

Y
[

A

8

25-30,32-34,44,46,50

1

S

[

M

4

37,38,47,49

2

L

Y

A
A
A
M*

8.5
8
8
5

22-61

1
3
1
2

S
M
S
M

[
[
[
Y

20,22-24,31,35-40,42-49,53-56,61

56
16-19,21-29,31,34-55,57-61

X

21,22,30,35,36,38-40,42,44,45,4749,54,56,57,61

Abbreviations: 3D Z 3-dimensional; IMRT Z intensity-modulated radiation therapy; RC Z radical cystectomy; RT Z radiation therapy.
Rating: A Z usually appropriate; M Z may be appropriate; U Z usually not appropriate.
Strength of evidence: S Z strong; M Z moderate; L Z limited; EC Z expert consensus; EO Z expert opinion.
Study quality: 1 Z well designed; 2 Z good quality; 3 Z good quality with limitations; 4 Z may not be useful as primary reference.
Strength of recommendation: [ Z strong recommendation; Y Z weak recommendation; - Z additional considerations do not strengthen or weaken the
panel’s recommendation.
* Disagreement (ie, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation; see
narrative text). Group median rating is set automatically to 5.

no difference in overall survival. Maciejewski et al generated a statistical model based on clinical data that predicted
a local control probability of 50% if a total of 63.3 Gy were
delivered within 40 days versus only 5% if the same were
delivered in 55 days.63 These 2 studies examined RT alone;
it is unknown whether time effects remain as influential
with concurrent chemotherapy. RTOG protocols with splitcourse and concurrent chemotherapy resulted in relatively
high local control rates despite treatment breaks. However,
the currently enrolling SWOG/NRG S1806 trial does not
allow for split-course RT. The panel did not reach a uniform
decision on the appropriateness of split-course RT, but
generally felt that this approach was more appropriate in
patients for whom cystectomy is an option (Tables 2-4).

What are the most appropriate RT fields?
RT treatment volumes vary significantly between clinical
trials. In RTOG trials and the University of Erlangen
studies, the pelvic lymph nodes are usually treated to
elective doses during the induction phase of the split-course
regimen.34,54,60,64 Elective pelvic lymph node irradiation
(PLNI) was incorporated into RTOG protocols based on

surgical series showing approximately a 25% risk of LNinvolvement in clinically node-negative patients.4,64 A full
pelvic volume (extending to the L5/S1 interspace superiorly) was treated in earlier RTOG trials and a small pelvic
volume (extending to S2/3 superiorly) was treated in later
RTOG trials.44 The tumor or whole bladder was then
boosted to the maximum dose during the consolidation
phase (in earlier trials) or as a concomitant boost during
induction (in later trials). In comparison, patients in
BC2001, TROG 97.01, and many European trials were
treated to the whole bladder plus a 1.5 to 2.0 cm
margin.24,27,34 These trials excluded clinically nodepositive patients, and all had rates of pelvic control comparable to trials which included pelvic nodal irradiation.
The rates of pelvic nodal failure in BC2001 and the TROG
trials were less than 10%. A randomized trial including 230
patients with cN0 MIBC compared CCRT with elective
whole pelvic RT versus same with bladder plus 2cm margin
only.60 At a median follow-up of 5 years, there was no
difference in DFS (47% vs 47%), OS (53% vs 51%), or rate
of bladder preservation (59% vs 57%). Acute grade 3 or 4
diarrhea was higher in patients receiving whole pelvic RT
and concurrent chemotherapy (3.9% vs 2%). There were no
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differences in late effects. Due to significant differences in
practices between North American and European clinicians, and historical use of elective pelvic LN fields,
members of the ARS bladder panel felt that elective PLNI
can be appropriate for patients with cT2-T4 cN0 M0 MIBC
(Tables 2-5).
Inclusion of the entire bladder within the clinical target
volume is partly motivated by surgical series revealing a
high rate of discordance in the primary tumor location
between urologists’ preoperative identification and that of
the actual cystectomy specimen.65 In BC2001, patients
were also randomized to whole bladder irradiation or whole
bladder irradiation to 80% prescription dose plus boost to
the tumor volume.66 Although a reduction in bladder volume receiving full dose was shown to be noninferior with
regards to local control, there was no demonstrated
advantage in toxicity. Similarly, a trial conducted at
Christie Hospital in the United Kingdom randomized 149
patients to either whole bladder or partial bladder (tumor
plus 1.5 cm margin) RT; disease control and toxicities were
not different.67 Both of the trials used 3-dimensional (3D)
approaches for RT, and it is unknown whether more
conformal techniques, such as intensity-modulated radiation therapy (IMRT), would be able to produce clinically
relevant differences in toxicity by better sparing uninvolved
bladder.

Patients with MIBC who are not operative
candidates or who refuse salvage cystectomy
The previous discussion also pertains to management of
medically inoperable patients or those who refuse upfront
radical cystectomy, with the exception that a split-course
regimen to assess for CR is typically unnecessary for
medically inoperable patients (Table 3).

Subtopic 1: In patients who cannot receive
chemotherapy, can definitive RT alone be offered?
Historically, radical RT alone was reserved for nonoperative
candidates and demonstrated 5-year overall survival rates
ranging from 16% to 28%.17,28-32 Total dose ranged from
60 Gy to 70 Gy in 2 Gy fractions and PLNI was typically
used. Many nonoperative candidates are also cisplatinineligible. In such cases, alternative chemotherapy agents
should be considered (eg, MMC/5FU, low-dose gemcitabine). The randomized clinical trial BC2001 revealed statistically significant improvements in LC and salvage rates,
but not OS, between RT and CRT.24 RT alone is a curative
treatment modality and patients who are not able to receive
concurrent chemotherapy, should be offered definitive RT
alone.
In Europe and some North American centers, concurrent
carbogen and nicotinamide (CON, a hypoxia modifier) are
used with RT in patients who are not candidates for CCRT.
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The BCON trial randomized 333 patients to either RT alone
or RT with carbogen gas (2% CO2 and 98% O2 at 15 L/min
and nicotinamide (40-60 mg/kg).68 Addition of CON
resulted in an 11% and 13% improvement in RFS and OS at
3 years, respectively. This improvement was even more
dramatic in patients with necrosis present in the TURBT
specimen, based on post hoc, histopathologic analysis.69
Although experience with RT þ CON is limited in North
America, this approach is evidence-based and should be
strongly considered in patients with MIBC who are ineligible for RC and cannot receive concurrent chemotherapy
with RT.

3D conformal versus intensity modulated RT
Nearly all trials reviewed used 3D conformal RT (3D-CRT)
technique (4- or 3-field box, see evidence table). A retrospective Danish study compared outcomes from 116 patients who received CCRT for MIBC with either 3D-CRT
(46 Gy to pelvis, followed by cone-down to bladder to 60
Gy in 2 Gy fractions) or IMRT (48 Gy to pelvis and
simultaneous integrated boost to bladder to 60 Gy in 2 Gy
fractions).70 IMRT significantly reduced dose to the small
bowel, resulting in a decrease in grade 2 diarrhea during
treatment (30% vs 56%, P Z .008), but there was no difference in late toxicity. The panel recommends both 3DCRT and IMRT as being appropriate (Tables 2-5).15

Conclusions
1. Patients with MIBC should be evaluated in a multidisciplinary tumor board, including a urologic oncologist,
medical oncologist, and radiation oncologist.
2. The panel strongly recommends that definitive radiation
therapy (with concurrent chemotherapy if tolerable or as
monotherapy) usually is appropriate for patients with
MIBC who are ineligible for radical cystectomy.
3. The panel conditionally recommends that responseadapted, selective bladder preservation (ie, definitive
radiation therapy for patients with CR after induction
phase of (chemo)RT or salvage cystectomy otherwise)
is usually appropriate for patients with MIBC who are
eligible for radical cystectomy but have adequate
baseline bladder function and wish to pursue organ
preservation. Organ preservation may be appropriate in
the subset of these patients with unilateral
hydronephrosis.
4. The panel strongly recommends that maximal TURBT
before definitive (chemo)RT usually is appropriate for
patients undergoing bladder-preserving RT for MIBC.
5. The panel strongly recommends that concurrent
chemotherapy (cisplatin alone, 5-FU/MMC, or low-dose
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gemcitabine) usually is appropriate for patients undergoing bladder-preserving RT for MIBC.
6. The panel conditionally recommends that neoadjuvant
chemotherapy (MCV or gemcitabine/cisplatin) before
(chemo)RT may be appropriate for patients undergoing
bladder-preserving RT for MIBC. Candidates for
cisplatin should have adequate renal function.
7. The panel conditionally recommends that adjuvant
chemotherapy after (chemo)RT may be appropriate for
patients undergoing bladder-preserving RT for MIBC, if
patients have not received neoadjuvant chemotherapy.
8. The panel strongly recommends that a maximal dose of
60 to 66 Gy in 2 Gy daily fractions is usually appropriate
for definitive (chemo)RT given as a continuous treatment
course with no planned breaks.

6.

7.

8.

9.

10.

11.

12.

9. The panel conditionally recommends that a maximal
dose of 60 to 66 Gy in 2 Gy daily fractions given as a
split-course is usually appropriate for definitive (chemo)
RT for patients who are candidates for cystectomy to
evaluate the response and offer early salvage cystectomy
in case of nonresponse.

13.

14.

10. The panel conditionally recommends that elective pelvic nodal irradiation may be appropriate for patients
undergoing bladder-preserving RT for MIBC.
11. The panel strongly recommends that 3D-conformal RT
or IMRT are both usually appropriate for patients undergoing bladder-preserving RT for MIBC. IMRT may
provide better sparing of organs at risk, while 3Dconformal RT may be preferred if there is concern for
significant target motion or lack of image guidance
capabilities.
12. The panel conditionally recommends that addition of
concurrent carbogen or nicotinamide to radiation therapy may be appropriate for patients with MIBC who are
not candidates for concurrent chemotherapy.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J
Clin 2019;69:7-34.
2. Stein J, Lieskovsky G, Cote R, et al. Radical cystectomy in the
treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
3. Hautmann RE, Gschwend JE, De Petriconi RC, et al. Cystectomy for
transitional cell carcinoma of the bladder: Results of a surgery only
series in the neobladder era. J Urol 2006;176:486-492.
4. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy
for bladder cancer todaydA homogeneous series without neoadjuvant
therapy. J Clin Oncol 2003;21:690-696.
5. Caffo O, Fellin G, Graffer U, Luciani L. Assessment of quality of life
after cystectomy or conservative therapy for patients with infiltrating

15.

16.
17.

18.

19.

20.

21.

22.

23.

24.

25.

961

bladder carcinoma a survey by a self-administered questionnaire.
Cancer 1996;76:1089-1097.
Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy
in patients undergoing radical cystectomy: A high-volume tertiary
cancer center experience. Eur Urol 2009;55:177-186.
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